# Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

> **NCT00840450** · PHASE2 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 14 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Gleevec/Paclitaxel

## Key facts

- **NCT ID:** NCT00840450
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2010-04
- **Final completion:** 2012-10
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Due to slow accrual
- **Last updated:** 2012-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00840450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00840450, "Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00840450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*